{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:10:38Z","timestamp":1757542238242,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["5T32HD069054"],"award-info":[{"award-number":["5T32HD069054"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40262-020-00939-2","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T02:03:35Z","timestamp":1600308215000},"page":"249-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-9826","authenticated-orcid":false,"given":"Tomoyuki","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooks T.","family":"McPhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyog","family":"Kamatkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Wexelblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Christians","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry T.","family":"Akinbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"issue":"4","key":"939_CR1","doi-asserted-by":"publisher","first-page":"e20173520","DOI":"10.1542\/peds.2017-3520","volume":"141","author":"TNA Winkelman","year":"2018","unstructured":"Winkelman TNA, Villapiano N, Kozhimannil KB, Davis MM, Patrick SW. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004\u20132014. Pediatrics. 2018;141(4):e20173520.","journal-title":"Pediatrics"},{"issue":"8","key":"939_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/jp.2015.36","volume":"35","author":"SW Patrick","year":"2015","unstructured":"Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol. 2015;35(8):650\u20135.","journal-title":"J Perinatol"},{"issue":"25","key":"939_CR3","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1056\/NEJMra1600879","volume":"375","author":"K McQueen","year":"2016","unstructured":"McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375(25):2468\u201379.","journal-title":"N Engl J Med"},{"issue":"24","key":"939_CR4","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1056\/NEJMoa1614835","volume":"376","author":"WK Kraft","year":"2017","unstructured":"Kraft WK, Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. N Engl J Med. 2017;376(24):2341\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"939_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-0037-1608634","volume":"35","author":"ES Hall","year":"2018","unstructured":"Hall ES, Rice WR, Folger AT, Wexelblatt SL. Comparison of neonatal abstinence syndrome treatment with sublingual buprenorphine versus conventional opioids. Am J Perinatol. 2018;35(4):405\u201312.","journal-title":"Am J Perinatol"},{"issue":"7","key":"939_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","volume":"44","author":"A Elkader","year":"2005","unstructured":"Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"939_CR7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jpeds.2015.09.038","volume":"167","author":"ES Hall","year":"2015","unstructured":"Hall ES, Meinzen-Derr J, Wexelblatt SL. Cohort analysis of a pharmacokinetic-modeled methadone weaning optimization for neonatal abstinence syndrome. J Pediatr. 2015;167(6):1221\u20135.e1.","journal-title":"J Pediatr"},{"issue":"6","key":"939_CR8","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jpeds.2015.08.032","volume":"167","author":"JR Wiles","year":"2015","unstructured":"Wiles JR, Isemann B, Mizuno T, Tabangin ME, Ward LP, Akinbi H, et al. Pharmacokinetics of oral methadone in the treatment of neonatal abstinence syndrome: a pilot study. J Pediatr. 2015;167(6):1214\u201320.e3.","journal-title":"J Pediatr"},{"issue":"7","key":"939_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/phar.1610","volume":"35","author":"CM Ng","year":"2015","unstructured":"Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, et al. Population pharmacokinetic model of sublingual buprenorphine in neonatal abstinence syndrome. Pharmacotherapy. 2015;35(7):670\u201380.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"939_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/cpt.1064","volume":"103","author":"JN Moore","year":"2018","unstructured":"Moore JN, Gastonguay MR, Ng CM, Adeniyi-Jones SC, Moody DE, Fang WB, et al. The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome. Clin Pharmacol Ther. 2018;103(6):1029\u201337.","journal-title":"Clin Pharmacol Ther"},{"key":"939_CR11","volume-title":"Pharmacokinetics of buprenorphine in the neonatal abstinence syndrome","author":"S Kamatkar","year":"2017","unstructured":"Kamatkar S, Mizuno T, Ward LP, Isemann B, Vinks A, Akinbi H. Pharmacokinetics of buprenorphine in the neonatal abstinence syndrome. San Francisco: Pediatric Academic Societies; 2017."},{"issue":"1","key":"939_CR12","first-page":"141","volume":"2","author":"LP Finnegan","year":"1975","unstructured":"Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2(1):141\u201358.","journal-title":"Addict Dis"},{"issue":"3","key":"939_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00216-011-4775-z","volume":"400","author":"CF Clavijo","year":"2011","unstructured":"Clavijo CF, Hoffman KL, Thomas JJ, Carvalho B, Chu LF, Drover DR, et al. A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011;400(3):715\u201328.","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"939_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"key":"939_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"939_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/clpt.1994.155","volume":"56","author":"WJ Jusko","year":"1994","unstructured":"Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994;56(4):406\u201319.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"939_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40262-014-0155-0","volume":"53","author":"AF Nasser","year":"2014","unstructured":"Nasser AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet. 2014;53(9):813\u201324.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"939_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367.","journal-title":"N Engl J Med"},{"issue":"1","key":"939_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.930","volume":"103","author":"WK Kraft","year":"2018","unstructured":"Kraft WK. Buprenorphine in neonatal abstinence syndrome. Clin Pharmacol Ther. 2018;103(1):112\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"939_CR20","first-page":"12","volume":"5","author":"EM Wachman","year":"2016","unstructured":"Wachman EM, Schiff DM. Bringing attention to a need for a standardized treatment and weaning protocol for neonatal abstinence syndrome. Transl Pediatr. 2016;5(1):12\u20135.","journal-title":"Transl Pediatr"},{"issue":"4","key":"939_CR21","doi-asserted-by":"publisher","first-page":"e803","DOI":"10.1542\/peds.2015-1141","volume":"136","author":"ES Hall","year":"2015","unstructured":"Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. Implementation of a neonatal abstinence syndrome weaning protocol: a multicenter cohort study. Pediatrics. 2015;136(4):e803\u2013e810810.","journal-title":"Pediatrics"},{"issue":"2","key":"939_CR22","doi-asserted-by":"publisher","first-page":"e527","DOI":"10.1542\/peds.2013-4036","volume":"134","author":"ES Hall","year":"2014","unstructured":"Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics. 2014;134(2):e527\u2013e534534.","journal-title":"Pediatrics"},{"key":"939_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26470","author":"T Mizuno","year":"2017","unstructured":"Mizuno T, Fukuda T, Emoto C, Mobberley-Schuman PS, Hammill AM, Adams DM, et al. Developmental pharmacokinetics of sirolimus: implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatr Blood Cancer. 2017. https:\/\/doi.org\/10.1002\/pbc.26470.","journal-title":"Pediatr Blood Cancer."},{"issue":"6","key":"939_CR24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40262-018-0729-3","volume":"58","author":"T Mizuno","year":"2019","unstructured":"Mizuno T, Gist KM, Gao Z, Wempe MF, Alten J, Cooper DS, et al. Developmental pharmacokinetics and age-appropriate dosing design of milrinone in neonates and infants with acute kidney injury following cardiac surgery. Clin Pharmacokinet. 2019;58(6):793\u2013803.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"939_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/cpt.169","volume":"98","author":"AA Vinks","year":"2015","unstructured":"Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther. 2015;98(3):298\u2013308.","journal-title":"Clin Pharmacol Ther"},{"key":"939_CR26","unstructured":"Ohio Perinatal Quality Collaborative. https:\/\/www.opqc.net\/. Accessed 20 Jan 2020."},{"issue":"5","key":"939_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1124\/dmd.105.003681","volume":"33","author":"N Picard","year":"2005","unstructured":"Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005;33(5):689\u201395.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"939_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1124\/dmd.105.006148","volume":"34","author":"Y Chang","year":"2006","unstructured":"Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos. 2006;34(3):440\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"939_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1124\/dmd.109.029546","volume":"38","author":"K Rouguieg","year":"2010","unstructured":"Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010;38(1):40\u20135.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"939_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/papr.12152","volume":"15","author":"JA Sastre","year":"2015","unstructured":"Sastre JA, Varela G, Lopez M, Muriel C, Gonzalez-Sarmiento R. Influence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia. Pain Pract. 2015;15(1):22\u201330.","journal-title":"Pain Pract"},{"issue":"7","key":"939_CR31","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/papr.12343","volume":"16","author":"F Blanco","year":"2016","unstructured":"Blanco F, Muriel C, Labrador J, Gonzalez-Porras JR, Gonzalez-Sarmiento R, Lozano FS. Influence of UGT2B7, CYP3A4, and OPRM1 gene polymorphisms on transdermal buprenorphine pain control in patients with critical lower limb ischemia awaiting revascularization. Pain Pract. 2016;16(7):842\u20139.","journal-title":"Pain Pract"},{"issue":"17","key":"939_CR32","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2013.3411","volume":"309","author":"EM Wachman","year":"2013","unstructured":"Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA. 2013;309(17):1821\u20137.","journal-title":"JAMA"},{"issue":"1","key":"939_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/hpeds.2017-0128","volume":"8","author":"MR Grossman","year":"2018","unstructured":"Grossman MR, Lipshaw MJ, Osborn RR, Berkwitt AK. A novel approach to assessing infants with neonatal abstinence syndrome. Hosp Pediatr. 2018;8(1):1\u20136.","journal-title":"Hosp Pediatr"},{"issue":"8","key":"939_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1542\/hpeds.2018-0238","volume":"9","author":"T Blount","year":"2019","unstructured":"Blount T, Painter A, Freeman E, Grossman M, Sutton AG. Reduction in length of stay and morphine use for NAS with the \"eat, sleep, console\" method. Hosp Pediatr. 2019;9(8):615\u201323.","journal-title":"Hosp Pediatr"},{"issue":"2","key":"939_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/ANC.0000000000000581","volume":"19","author":"LM Grisham","year":"2019","unstructured":"Grisham LM, Stephen MM, Coykendall MR, Kane MF, Maurer JA, Bader MY. Eat, sleep, console approach: a family-centered model for the treatment of neonatal abstinence syndrome. Adv Neonatal Care. 2019;19(2):138\u201344.","journal-title":"Adv Neonatal Care"},{"issue":"4","key":"939_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jamapediatrics.2017.5195","volume":"172","author":"KDL MacMillan","year":"2018","unstructured":"MacMillan KDL, Rendon CP, Verma K, Riblet N, Washer DB, Volpe HA. Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatr. 2018;172(4):345\u201351.","journal-title":"JAMA Pediatr"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00939-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00939-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00939-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T23:23:24Z","timestamp":1631834604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00939-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00939-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"17 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brooks T. McPhail was supported by a Eunice Kennedy Shriver National Institute of Child Health and Human Development training Grant (5T32HD069054).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Scott Wexelblatt has received a research grant from Chiesi Pharmaceuticals and a consulting fee from Braeburn Pharmaceuticals. He is also on a speaker bureau to discuss treatment options for NOWS. These payments had no effect on this paper or results. Tomoyuki Mizuno, Brooks T. McPhail, Suyog Kamatkar, Laura Ward, Uwe Christians, Henry T. Akinbi, and Alexander A. Vinks have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TM, BTM, SK, SW, LW, UC, HTA, and AAV wrote the manuscript and designed the research. TM, BTM, SK, LW, UC, HTA, and AAV performed the research and analyzed the data.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}